Belumosudil and Rituximab for first-time chronic GVHD treatment
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are experiencing chronic GVHD for the first time and need treatment with medications that affect your whole body (systemic therapy).
- You have not taken more than 10 days of steroids or other similar medications specifically for this new diagnosis.
- You are up and about, capable of at least light work (Karnofsky Performance Status score of 70% or higher).
- Your blood cell counts are adequate without needing platelet transfusions or growth factor injections for at least a week.
- You do not have active infections, HIV, hepatitis B or C (unless successfully treated and virus is undetectable).
- Your kidney and liver function are within acceptable limits, and your heart is pumping well (ejection fraction 40% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This study tests two medications (belumosudil and ruxolitinib) together for chronic graft-versus-host disease (cGvHD)—a condition where transplanted immune cells attack your body—that did not improve with steroid treatment alone. The trial aims to help patients whose disease is resistant to standard steroids.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.